MiNK Therapeutics: KDJ Golden Cross, Bullish Marubozu Pattern on 15-Minute Chart

MiNK Therapeutics's 15-minute chart recently exhibited a bullish signal, as evidenced by the KDJ Golden Cross and the appearance of a bullish Marubozu candlestick pattern on August 29th at 12:00. This indicates that the momentum of the stock price is shifting towards the upside and has the potential to continue increasing. The current market conditions suggest that buyers are in control, and it is likely that bullish momentum will persist.

Agenus Inc. (Nasdaq: AGEN), a leading immuno-oncology company, has announced an update to its virtual Stakeholder Briefing scheduled for August 27, 2025, at 4:00 p.m. ET. The webcast will introduce a new virtual format to enhance attendee engagement and will feature an updated participation link [1].

The webcast will cover a strategic and financial overview, Zydus partnership momentum and execution, patient needs fueling interest in colorectal cancer (CRC) studies, recent BOT/BAL clinical updates, and an overview of the Phase 3 BATTMAN study in metastatic CRC. Additionally, the session will include a spotlight on MiNK Therapeutics, of which Agenus is a significant stakeholder, and upcoming milestones across the portfolio. The webcast will conclude with a live Q&A session [1].

Key speakers include Garo H. Armen, PhD, Founder, Chairman, and CEO of Agenus; Richard M. Goldberg, MD, Chief Development Officer; Nicholas C. DeVito, MD, Assistant Professor of Medical Oncology at Duke University; Chris O'Callaghan, DVM, MSc, PhD, Senior Investigator at Canadian Cancer Trials Group (CCTG); and Jen Buell, PhD, Chief Executive Officer, MiNK Therapeutics [1].

Agenus is a leading immuno-oncology company with a comprehensive pipeline of immunological agents. The company was founded in 1994 and focuses on expanding patient populations benefiting from cancer immunotherapy through combination approaches. Agenus has robust end-to-end development capabilities across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint [1].

The company's pipeline includes Botensilimab (BOT), a multifunctional, human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Botensilimab has shown clinical responses across nine metastatic, late-line cancers in phase 1 and phase 2 clinical trials. Approximately 1,200 patients have been treated across the botensilimab/balstilimab program [1].

Balstilimab (BAL) is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types [1].

Agenus has also highlighted the potential benefits of the combination therapy of Botensilimab and Balstilimab, which has shown clinical responses across nine metastatic, late-line cancers. The company cautions investors not to place undue reliance on forward-looking statements, as actual results may differ materially from current expectations [1].

References:
[1] https://www.marketscreener.com/news/agenus-aug-27-stakeholder-webcasta-transformative-io-updates-bot-bal-data-battman-preview-zydus-ce7c50d9da8bf12d